TOKYO--(BUSINESS WIRE)--Solasia Pharma K.K. (http://www.solasia.co.jp/en/index.html), a developer of Western oncology pharmaceuticals in-licensed for commercialization in Asian markets, announced today initiation of a Phase 1 study of SP-01 (long-acting transdermal granisetron patch; brand name: Sancuso®) in Japanese volunteers. This represents the first study implemented by Solasia.
